Avion, Announces Phase 2 Clinical Data of Vabametkib at 'ASCO' "Encouraging Response as Monotherapy"

[Financial News] Avion announced on the 27th that it will present the global phase 2 monotherapy data of its leading anticancer drug candidate 'Vabametkib (Vabametkib·ABN401)' at the annual meeting of the American Society of Clinical Oncology (ASCO) in the United States. The event will be held in Chicago, USA, from the 29th to the 2nd of next month.
Vabametkib is a treatment for MET mutation-positive non-small cell lung cancer (NSCLC) and is undergoing phase 2 clinical trials in the United States, Taiwan, and Korea. In the phase 2 monotherapy group, Vabametkib recorded an objective response rate (ORR) of 43.2% and a disease control rate (DCR) of 97.3%. In particular, the proportion of patients showing a partial response (PR) reached 43%.
Avion emphasized that this result suggests not only the potential as a monotherapy but also the possibility of combination with immune checkpoint inhibitors (ICI). Notably, they highlighted the high PR response observed in patient groups who received first-line treatment with the immune checkpoint inhibitor Keytruda (pembrolizumab), expressing expectations for market expansion possibilities targeting combination therapy or patients who discontinued treatment.
A company representative said, "We plan to also disclose 'Trial in Progress' data on the ongoing combination therapy cohort (Cohort 2) at 'ASCO'," adding, "Based on additional data, we will consider combination trials with PD-1/PD-L1 class drugs if necessary."
Meanwhile, Avion signed a letter of intent (LOI) term sheet in April with a Russia-based global pharmaceutical company for the technology transfer of Vabametkib targeting Russia and four CIS countries.
dschoi@fnnews.com Choi Doo-sun Reporter